Answers are grounded in this paper and cite their sources.
Retrospective analysis examined one-year survival and healthcare utilization in liver transplant patients, suggesting implications for resource allocation.
Background: Acute-on-chronic liver failure (ACLF) has been associated with excellent post- liver transplant (LT) outcomes at one year, however the impact of alcohol as ACLF precipitant, specifically alcohol-associated hepatitis (AH), and as etiology of chronic liver disease (CLD) remains uncertain. This study aimed to assess the effect of alcohol as ACLF precipitant and CLD etiology (alcohol-associated liver disease (ALD) vs. non-ALD) on post-transplant outcomes. Methods: We performed a retrospective study using the Multi-Organ Dysfunction and Evaluation for LT Consortium database and included 640 patients with ACLF who underwent LT across 15 transplant centers in North America. The primary outcome was one-year post-transplant survival. We used logistic regression and Cox proportional hazards to compare post-transplant survival, mortality risk, and healthcare utilization, adjusting for age, ACLF grade, comorbid diabetes mellitus (DM), chronic kidney disease (CKD), and hepatocellular carcinoma (HCC). Results: Median follow-up from LT was 2.8 years (P25-P75, 2.2-5.5 y) for AH-ACLF (n=42) patients and 3.1 years (P25-P75, 1.6-4.9 y) for non-AH patients (n=598). No significant difference was observed in one-year survival post-LT in patients with AH-ACLF versus non-AH ( p =0.36). AH patients had significantly higher healthcare utilization evidenced by greater length of stay (28.5 vs. 19.0 d, p =0.004; adjusted linear estimate 16.89, 95% CI 7.66-26.11, p <0.001), higher rates of rehabilitation placement (71.4% vs. 41.8%, p =0.002; aOR 4.13, 95% CI 2.04 to 8.89, p <0.001), and non-ambulatory status (39.0% vs. 21.0%, p =0.005; aOR 4.54, 95% CI 1.90-10.79, p <0.001). Compared to other etiologies, ALD was not associated with differences in 1-year mortality, mortality risk over time, or healthcare utilization, after excluding patients with AH as ACLF precipitant. Conclusion: While there were no differences in one year survival, AH-ACLF was associated with higher healthcare resource utilization compared to other ACLF precipitants. Liver transplant centers should ensure adequate resources are allocated for management of these patients.
No takes yet. Share an insight, caveat, or question.
Kusztos et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: